PTBS
Studienlage · Detail Systematic Review · PTBS · 2024

A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters.

Gemischt GRADE Hoch 16 Zitate
Stichprobek = 14 Studien
DauerStudien von Januar 1990 bis…
EndpunktPTSD-Symptombelastung
Verblindungunklar
DesignSystematic Review
Kernaussage

Bei PTSD ohne komorbide Cannabinoidstörung zeigten 5 von 10 Studien Nutzen und 5 keinen Effekt oder Verschlechterung; bei komorbider Störung alle 3 Studien Risiken für Symptomverschlechterung; einige Vorteile für Cluster-B- und E-Symptome beobachtet.

Zusammenfassung

Systematische Review zu Cannabis/Cannabinoiden bei PTSD (Januar 1990–Februar 2023); k=14 Studien (3 in komorbider PTSD+CUD-Stichprobe, 11 in Nicht-CUD-Stichprobe). Von 10 Studien zu Gesamt-PTSD-Symptomen (Nicht-CUD): 5 berichteten Nutzen, 5 keinen Effekt oder Verschlechterung. 4 Studien zeigten Nutzen für Cluster-B- und -E-Symptome. Alle 3 Studien bei komorbider CUD berichteten Risiken für Symptomverschlechterung. Keine wesentlichen Vorteile für Gesamt-PTSD-Symptome; einige Risiken bzgl. Suizidalität und Gewaltverhalten.

P
PopulationErwachsene mit PTSD, davon 3 Studien mit komorbider Cannabis-Gebrauchsstörung (CUD), 11 ohne CUD
I
InterventionCannabis und Cannabinoide (verschiedene Formen)
O
Outcome5/10 Studien zeigten Nutzen für PTSD-Gesamtsymptomatik, 5/10 keinen Effekt oder Verschlechterung; Nutzen für Cluster-B- und -E-Symptome in 4 Studien; alle 3 CUD-Studien zeigten Risiko für Symptomverschlechterung
Vertrauen in die Evidenz
Hoch

Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.

Qualitätsprofil
Größe
Verblindung
Effektstärke Gemischt
Zitate / Jahr
Autoren
Rodas JD, George TP, Hassan AN
DOI 10.4088/jcp.23r14862
Design: Systematic Review
Teilen
Abstract
Objective: Given the high rate of comorbid posttraumatic stress disorder (PTSD) and cannabis use, it is critical that further research be conducted to address the associated benefits and risks of cannabis use in this population. This systematic review evaluated evidence on the effects of cannabis and cannabinoids on PTSD symptoms and PTSD clusters. Data Sources: A systematic search of PubMed, PsycINFO, and EMBASE databases was performed using terms related to cannabis, cannabinoids, and PTSD. Peer-reviewed studies available online in English and published from January 1990 through February 2023 were considered. Study Selection: Included studies were experimental or observational in design, were conducted in cannabis-using patients with PTSD, used validated measures of PTSD, and were published in English. Data Extraction: Extracted information included study aims, study design, sample size and sex, comparator group, cannabis-related characteristics, psychometric instruments, and relevant clinical findings regarding overall PTSD symptoms and cluster symptoms. Results: Fourteen studies were included, 3 in a comorbid PTSD and cannabis use disorder (CUD) sample and 11 in a non-CUD sample. Of the 10 studies examining overall PTSD symptoms in a non-CUD sample, 5 suggested benefits associated with cannabis use and 5 suggested no effect or worsening of symptoms. Four studies reported benefits of cannabis for cluster B- and E-related symptoms in a non-CUD sample. All 3 studies in cannabis-using patients with a comorbid PTSD and CUD diagnosis reported risks for worsening of overall symptoms. Conclusions: This review did not find major benefits of cannabinoids in improving overall PTSD symptoms. Some benefits with regard to cluster B and E symptoms were observed. Some risks with regard to worsening suicidal ideation and violent behavior were also reported. Individuals with a comorbid CUD diagnosis may be at greater risk for negative cannabis-related PTSD outcomes. More experimental studies are needed to determine the causal effects of cannabis and cannabinoids in PTSD.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel